The Array 5 – Multiple Autoimmune Reactivity Screen from Cyrex Laboratories assesses autoantibodies predictive for certain diseases. It determines potential tissue damage in various body organs, including cardiovascular, endocrine, joint, gastrointestinal, and neurological.
Early detection of autoimmunity is helpful in potentially halting or reversing disease progression.
The Array 5 – Multiple Autoimmune Reactivity Screen measures Predictive Antibodies and self-targeting indicators for acquiring particular autoimmune diseases in the future.
As the Array 5 – Multiple Autoimmune Reactivity Screen produces results that can predict some illnesses up to 10 years in advance.
It is a beneficial test for patients with a diagnosed autoimmune condition, those at risk for developing autoimmune diseases, or patients with chronic increased intestinal permeability with potential for environmentally-induced autoimmune issues.
Some common patient types this test is beneficial for are:
The Array 5 – Multiple Autoimmune Reactivity Screen requires a blood sample for analysis. The specimen collection kit includes blood collection tubes and return packaging. The sample is to be collected by a phlebotomist using the tubes supplied and then shipped to Cyrex Laboratories for evaluation. Results are sent to your Rupa Health Portal!
Measures IgG and IgA antibodies against different tissue antigens that are found from head to toe. These tissues are involved in more than 90 different autoimmune diseases. Detection of antibodies against these antigens at the early stage helps in the prevention and management of many autoimmune disorders since these predictive antibodies can be detected 3-19 years before the development of the clinical stage of an autoimmune disease. Developed and published by Aristo Vojdani, PhD, MSc, CLS, known as the father of functional immunology, in 2008, 2020, 2021, 2023, and 2024.
.svg){kind=small}
.svg){kind=small}
On December 11th, join Dr. Terry Wahls in a 
